Basilea Pharmaceutica AG (BSLN.SW) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. BSLN.SW files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.88% | 30.00% | Pass |
| Interest-bearing investments | 19.99% | 30.00% | Pass |
| Non-permissible income | 0.55% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 36.52% | 33.00% | Fail |
| Interest-bearing investments | 56.67% | 33.00% | Fail |
| Non-liquid assets | 38.55% | at least 20.00% | Pass |
| Non-permissible income | 0.55% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 36.52% | 33.33% | Fail |
| Cash + interest-bearing securities | 56.67% | 33.33% | Fail |
| Accounts receivable | 61.45% | 33.33% | Fail |
| Non-permissible income | 0.55% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 36.52% | 33.33% | Fail |
| Cash + interest-bearing securities | 56.67% | 33.33% | Fail |
| Accounts receivable | 61.45% | 50.00% | Fail |
| Non-permissible income | 0.55% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.61% | 33.00% | Pass |
| Cash + interest-bearing securities | 27.32% | 33.00% | Pass |
| Accounts receivable | 2.31% | 33.00% | Pass |
| Non-permissible income | 0.55% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 18.93% | 33.00% | Pass |
| Cash + interest-bearing securities | 29.38% | 49.00% | Pass |
| Accounts receivable | 2.48% | 49.00% | Pass |
| Non-permissible income | 0.55% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 18.93% | 33.33% | Pass |
| Cash + interest-bearing securities | 29.38% | 33.33% | Pass |
| Accounts receivable | 31.86% | 49.00% | Pass |
| Non-permissible income | 0.55% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 71.40 | SELL |
| Stochastic %K (14) | 80.77 | SELL |
| CCI (20) | 68.21 | NEUTRAL |
| Williams %R (14) | -19.23 | SELL |
| MACD (12,26,9) | -0.20 | SELL |
| ROC (10) | 1.53 | BUY |
| Momentum (10) | 1.00 | BUY |
| EMA (10) | 64.60 | BUY |
| SMA (10) | 64.69 | BUY |
| EMA (20) | 62.69 | BUY |
| SMA (20) | 63.37 | BUY |
| EMA (30) | 60.93 | BUY |
| SMA (30) | 59.48 | BUY |
| EMA (50) | 58.61 | BUY |
| SMA (50) | 56.82 | BUY |
| EMA (100) | 56.03 | BUY |
| SMA (100) | 54.61 | BUY |
| EMA (200) | 53.99 | BUY |
| SMA (200) | 54.12 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold infections; ceftibuten-ledaborbactam etzadroxil, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe enterobacteriaceae infections. The company has a strategic collaboration with Prokaryotics, Inc for the development of broad-spectrum antifungal targeting drug-resistant pathogens through a differentiated mechanism of action; and Phare Bio, a biotech social venture to leverage generative artificial intelligence (AI) to transform antibiotic discovery. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.